Literature DB >> 6134748

Sequential serum measurements of thyrotropin binding inhibitor immunoglobulin G in transient familial neonatal hypothyroidism.

M Iseki, M Shimizu, T Oikawa, H Hojo, K Arikawa, Y Ichikawa, N Momotani, K Ito.   

Abstract

Infants with transient neonatal hypothyroidism, in whom TSH binding inhibitor immunoglobulin G (IgG) (TBII) were sequentially measured, are described. Their mother had been taking thyroid replacement for hypothyroidism due to nongoitrous autoimmune thyroiditis. IgGs inhibiting TSH binding were detected in maternal sera by radioreceptor assay. These IgGs also inhibited the adenylate cyclase response to TSH in human thyroid membranes. Three infants had frank hypothyroidism immediately after birth, and TBII were detected in two of them. In the two surviving infants, hypothyroidism was transient and improved when TBII disappeared from their sera. The profile of TBII in one patient corresponded to the IgG disappearance curve. These findings suggest that the transient neonatal hypothyroidism reported was caused by transplacental transfer of TBII.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134748     DOI: 10.1210/jcem-57-2-384

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity.

Authors:  Y Li; J Kim; T Diana; R Klasen; P D Olivo; G J Kahaly
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

Review 2.  The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management.

Authors:  C A Koch; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 5.467

Review 3.  Thyrotropin Receptor Blocking Antibodies.

Authors:  Tanja Diana; Paul D Olivo; George J Kahaly
Journal:  Horm Metab Res       Date:  2018-10-04       Impact factor: 2.936

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.